XSHE
000950
Market cap1.34bUSD
Oct 09, Last price
5.34CNY
1D
2.10%
1Q
3.09%
Jan 2017
-43.01%
Name
C.Q. Pharmaceutical Holding Co Ltd
Chart & performance
P/E
23.65
P/S
0.11
EPS
0.23
Div yield, %
0.57%
Shrs. gr., 5y
0.28%
Rev. gr., 5y
5.69%
Revenues
82.45b
+2.34%
Net income
387m
+36.65%
CFO
755m
P
Dividend
Jun 18, 20260.03 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
C.Q. Pharmaceutical Holding Co., Ltd. is a pharmaceutical company primarily involved in the development, manufacturing, and distribution of medicinal products. Established in 1950, the firm has its headquarters in Chongqing, China. Its historical lineage includes Chongqing Medicines Co., Ltd., which was previously known as the Southwest Branch of China Medicine Company. C.Q. Pharmaceutical Holding Co., Ltd. operates as a subsidiary of Chongqing Chemical & Pharmaceutical Holding Group Company.
Key people
Quan Yuan
Chairman of the Board · since 2023
Shun Zhang
Chief Compliance Officer, General Counsel · since 2024
Wei Liu
General Manager, Director · since 2023
Deputy General Manager · since 2025
Deputy General Manager · since 2025
Qinghua Yang
Deputy General Manager · since 2023
Tian Qiu
Chief Financial Officer, Secretary of the Board · since 2022
Yihai Chen
Deputy General Manager, Director · since 2023
Fei Cheng
Director · since 2024
Shaohong Li
Executive Deputy General Manager, Director · since 2021
Yun Wei
Director · since 2023
Zhen Zeng
Director · since 2021
Zhongxi Cai
Independent Director · since 2023
Fengwen Chen
Independent Director · since 2023
Independent Director · since 2023
Hong Liu
Independent Director · since 2023
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||||
Revenues | |||||||||||
Cost of revenue | |||||||||||
Unusual Expense (Income) | |||||||||||
NOPBT | |||||||||||
NOPBT Margin | |||||||||||
Operating Taxes | |||||||||||
Tax Rate | |||||||||||
NOPAT | |||||||||||
Net income | |||||||||||
Dividends | |||||||||||
Dividend yield | |||||||||||
Proceeds from repurchase of equity | |||||||||||
BB yield | |||||||||||
| Debt | |||||||||||
Debt current | |||||||||||
Long-term debt | |||||||||||
Deferred revenue | |||||||||||
Other long-term liabilities | |||||||||||
Net debt | |||||||||||
| Cash flow | |||||||||||
Cash from operating activities | |||||||||||
CAPEX | |||||||||||
Cash from investing activities | |||||||||||
Cash from financing activities | |||||||||||
FCF | |||||||||||
| Balance | |||||||||||
Cash | |||||||||||
Long term investments | |||||||||||
Excess cash | |||||||||||
Stockholders' equity | |||||||||||
Invested Capital | |||||||||||
ROIC | |||||||||||
ROCE | |||||||||||
| EV | |||||||||||
Common stock shares outstanding | |||||||||||
Price | |||||||||||
Market cap | |||||||||||
EV | |||||||||||
EBITDA | |||||||||||
EV/EBITDA | |||||||||||
Interest | |||||||||||
Interest/NOPBT | |||||||||||